JOHNSON & JOHNSON

JNJ | NYSE | CIK: 0000200406 | SIC: 2834 Pharmaceutical Preparations | active
Johnson & Johnson is a global healthcare holding company with approximately 138,200 employees operating in virtually all countries. It is organized into two segments: Innovative Medicine (pharmaceuticals across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolism) and MedTech (cardiovascular, orthopaedics, surgery, and vision products). Key products include DARZALEX, STELARA, TREMFYA, CARVYKTI, SPRAVATO, XARELTO, and ACUVUE contact lenses.
oncologyimmunologyneurosciencepulmonary-hypertensioninfectious-diseases-(hiv/aids)cardiovascular-and-metabolismelectrophysiologymechanical-circulatory-supportorthopaedicssurgeryvision-care
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/JNJ
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
DARZALEX / DARZALEX FASPRO (daratumumab)serviceTreatment for multiple myeloma and light chain AL Amyloidosis; largest product at ~15% of total revenues.
STELARA (ustekinumab)serviceTreatment for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; second largest product at ~6.5% of revenues.
TREMFYA (guselkumab)serviceTreatment for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; third largest product at ~5.5% of revenues.
CARVYKTI (ciltacabtagene autoleucel)serviceCAR-T-cell therapy for relapsed/refractory multiple myeloma.
ERLEADA (apalutamide)serviceNext-generation androgen receptor inhibitor for prostate cancer treatment.
IMBRUVICA (ibrutinib)serviceTreatment for B-cell malignancies and chronic graft versus host disease.
RYBREVANT (amivantamab)serviceBispecific antibody for EGFR-mutated non-small cell lung cancer in adults.
LAZCLUZE (lazertinib)serviceOral, brain-penetrant EGFR tyrosine kinase inhibitor for non-small cell lung cancer.
TALVEY (talquetamab-tgvs)serviceBispecific antibody for relapsed or refractory multiple myeloma after four prior lines of therapy.
TECVAYLI (teclistamab-cqyv)serviceBispecific antibody for relapsed or refractory multiple myeloma after four prior lines of therapy.

Partnerships

PartnerTypeDescription
Genmab A/SlicensingExclusive license to two DARZALEX patent families; royalty rate 12%-20% of net sales, ~$2.4B paid in fiscal 2025.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/JNJ/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub